within Pharmacolibrary.Drugs.R_RespiratorySystem.R03B_OtherDrugsForObstructiveAirwayDiseasesInhalants.R03BA03_Flunisolide;

model Flunisolide
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 2.166666666666667e-05,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.002,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Flunisolide</td></tr><tr><td>ATC code:</td><td>R03BA03</td></tr><td>route:</td><td>inhalation</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>2.0</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.3</td><td>L/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Flunisolide is a synthetic corticosteroid with anti-inflammatory properties, commonly used as an inhaled medication for the prophylactic and symptomatic treatment of asthma. It is administered via inhalation route and is approved for use in many countries as an asthma controller medication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated based on typical information available for inhaled corticosteroids, as no direct population PK study with compartment modeling and full PK parameters for inhaled flunisolide in humans could be identified in the public literature.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R03BA03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Flunisolide;
